Case Reports:

A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy

Matteo Torresetti _, Donatella Brancorsini, Francesca Morgese, Valeria Cognigni, Alessandro Scalise, Rossana Berardi and Giovanni Di Benedetto

PDF  |  Full Text  |  How to cite

Oncotarget. 2020; 11:3256-3262. https://doi.org/10.18632/oncotarget.27701

Metrics: PDF 742 views  |   Full Text 1217 views  |   ?  


Matteo Torresetti1, Donatella Brancorsini2, Francesca Morgese3, Valeria Cognigni3, Alessandro Scalise1, Rossana Berardi3 and Giovanni Di Benedetto1

1 Clinic of Plastic and Reconstructive Surgery, Marche Polytechnic University Medical School, Ancona, Italy

2 Section of Pathological Anatomy, Marche Polytechnic University Medical School, Ancona, Italy

3 Clinic of Medical Oncology, Marche Polytechnic University Medical School, Ancona, Italy

Correspondence to:

Matteo Torresetti,email: [email protected]

Keywords: sarcomatoid melanoma; giant melanoma; BRAF mutation; targeted therapy; next-generation sequencing

Received: May 11, 2020     Accepted: July 21, 2020     Published: August 25, 2020


Sarcomatoid melanoma is an extremely rare pattern of malignant melanoma, and only few cases have been described throughout the literature. We herein report a case of a patient with newly diagnosed, metastatic giant sarcomatoid melanoma of the arm. The patient underwent surgical removal of the huge mass, and NGS sequencing demonstrated BRAF V600E mutation.

In view of histological, immunohistochemical and molecular findings, a combined BRAF/MEK inhibitor (BRAF/MEK-i) therapy was prescribed as first line treatment. A complete response (over one year) to targeted therapy was obtained, and no adverse events have been reported. The patient maintained a full range of shoulder and elbow movements, and she is able to live independently and resume her daily activities. We therefore recommend that all patients with undifferentiated melanomas, sarcomatoid cutaneous malignancies or other mesenchymal tumours, should undergo BRAFV600E mutation testing.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27701